Biophytis receives FDA approval for a Phase 2 OBA study of its obesity drug BIO101.

Biophytis, a French-American clinical-stage biotech company, has received FDA approval for its Phase 2 OBA study involving its drug BIO101 (20-hydroxyecdysone) in treating obesity. The study aims to measure the improvement in lower limb muscle strength and assess mobility and body composition changes. Dr. Marc-André Cornier, a renowned medical expert in obesity, will lead the study.